These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 28704915)

  • 1. Treatment of diabetic kidney disease: current and future targets.
    Kim MK
    Korean J Intern Med; 2017 Jul; 32(4):622-630. PubMed ID: 28704915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New progress in drugs treatment of diabetic kidney disease.
    Wang J; Xiang H; Lu Y; Wu T; Ji G
    Biomed Pharmacother; 2021 Sep; 141():111918. PubMed ID: 34328095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?
    Cherney DZ; Perkins BA
    Can J Diabetes; 2014 Oct; 38(5):356-63. PubMed ID: 25192954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New.
    Goldenberg RM; Berall M; Chan CTM; Cherney DZI; Lovshin JA; McFarlane PA; Senior PA; Verma S; Weinstein JJ
    Can J Diabetes; 2018 Jun; 42(3):325-334. PubMed ID: 28822777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
    Penno G; Garofolo M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does antihypertensive treatment with renin-angiotensin system inhibitors prevent the development of diabetic kidney disease?
    Miyazaki H; Babazono A; Nishi T; Maeda T; Imatoh T; Ichiba M; Une H
    BMC Pharmacol Toxicol; 2015 Sep; 16():22. PubMed ID: 26362195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the pharmacotherapeutic management of diabetic kidney disease.
    Block TJ; Batu D; Cooper ME
    Expert Opin Pharmacother; 2022 May; 23(7):791-803. PubMed ID: 35522659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New strategies to tackle diabetic kidney disease.
    Batu Demir D; Cooper ME
    Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):348-54. PubMed ID: 27138228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in glucose-lowering treatment to reduce diabetic kidney disease.
    Hanssen NM; Russell N; Cooper ME
    Expert Opin Pharmacother; 2015 Jun; 16(9):1325-33. PubMed ID: 25912195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies.
    Warren AM; Knudsen ST; Cooper ME
    Expert Opin Ther Targets; 2019 Jul; 23(7):579-591. PubMed ID: 31154867
    [No Abstract]   [Full Text] [Related]  

  • 12. Diagnosis and Management of Type 2 Diabetic Kidney Disease.
    Doshi SM; Friedman AN
    Clin J Am Soc Nephrol; 2017 Aug; 12(8):1366-1373. PubMed ID: 28280116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent therapeutic targets in diabetic nephropathy.
    Mohsen M; Elberry AA; Mohamed Rabea A; Abdelrahim MEA; Hussein RRS
    Int J Clin Pract; 2021 Nov; 75(11):e14650. PubMed ID: 34310818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on role of direct renin inhibitor in diabetic kidney disease.
    Dhakarwal P; Agrawal V; Kumar A; Goli KM; Agrawal V
    Ren Fail; 2014 Jul; 36(6):963-9. PubMed ID: 24678880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.
    Barrera-Chimal J; Jaisser F
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():16-31. PubMed ID: 32267077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive Treatment in Diabetic Kidney Disease: The Need for a Patient-Centered Approach.
    Bonino B; Leoncini G; De Cosmo S; Greco E; Russo GT; Giandalia A; Viazzi F; Pontremoli R
    Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31315312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets.
    Pichler R; Afkarian M; Dieter BP; Tuttle KR
    Am J Physiol Renal Physiol; 2017 Apr; 312(4):F716-F731. PubMed ID: 27558558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy.
    Johnson SA; Spurney RF
    Am J Physiol Renal Physiol; 2015 Nov; 309(10):F807-20. PubMed ID: 26336162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential for renoprotection with incretin-based drugs.
    Tanaka T; Higashijima Y; Wada T; Nangaku M
    Kidney Int; 2014 Oct; 86(4):701-11. PubMed ID: 25007170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.